Targeted nanotechnology for cancer imaging

Advanced Drug Delivery Reviews

Volumn 76, Issue 1, 2014, Pages 79-97

  Toy, Randall ^a,b   Bauer, Lisa ^b   Hoimes, Christopher ^a,c   Ghaghada, Ketan B ^d,e   Karathanasis, Efstathios ^a,b,f  

^a Case Western Reserve University   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d TEXAS CHILDREN S HOSPITAL   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer imaging; CT; MRI; Optical imaging; PET; SPECT; Targeted nanoparticles; Ultrasound

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DISEASES; MAGNETIC RESONANCE IMAGING; MEDICAL IMAGING; NANOPARTICLES; OPTICAL IMAGE STORAGE; POLYETHYLENE TEREPHTHALATES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; ULTRASONIC APPLICATIONS; ULTRASONICS;

BIOCHEMICAL INTERACTIONS; CANCER IMAGING; CLINICAL TRANSLATION; CONTRAST SENSITIVITY; OPTICAL IMAGING; SPECT; TARGETED NANOPARTICLE; X-RAY COMPUTED TOMOGRAPHY;

NANOMAGNETICS;

CHEMOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTEGRIN; LIGAND; NANOPARTICLE; QUANTUM DOT; TRANSFERRIN RECEPTOR; UROKINASE; CONTRAST MEDIUM;

ARTICLE; CANCER DIAGNOSIS; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; FLUORESCENCE IMAGING; HUMAN; NANOIMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE PROPERTY; ANIMAL; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; NEOPLASMS; PROCEDURES;

ANIMALS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS;

EID: 84928198129     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.08.002     Document Type: Review

References (251)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
2. Altundag K., Dede D.S., Purnak T. Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma. J. Clin. Pathol. 2007, 60:958.
3. Chakravarthy A.B., Kelley M.C., McLaren B., Truica C.I., Billheimer D., Mayer I.A., Grau A.M., Johnson D.H., Simpson J.F., Beauchamp R.D., Jones C., Pietenpol J.A. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin. Cancer Res. 2006, 12:1570-1576.
4. Heath J.R., Davis M.E. Nanotechnology and cancer. Annu. Rev. Med. 2008, 59:251-265.
5. Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. Oncologist 2003, 8(Suppl. 2):10-16.
6. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 2000, 65:271-284.
7. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
8. Lasic D.D. Doxorubicin in sterically stabilized liposomes. Nature 1996, 380:561-562.
9. Lasic D.D., Papahadjopoulos D. Liposomes revisited. Science 1995, 267:1275-1276.
10. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003, 8(Suppl. 2):17-24.
11. Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano 2013, 7:7442-7447.
12. Schroeder A., Heller D.A., Winslow M.M., Dahlman J.E., Pratt G.W., Langer R., Jacks T., Anderson D.G. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer 2012, 12:39-50.
13. Adiseshaiah P.P., Hall J.B., McNeil S.E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:99-112.
14. Kinkel K., Lu Y., Both M., Warren R.S., Thoeni R.F. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002, 224:748-756.
15. Bipat S., van Leeuwen M.S., Comans E.F., Pijl M.E., Bossuyt P.M., Zwinderman A.H., Stoker J. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis - meta-analysis. Radiology 2005, 237:123-131.
16. Niekel M.C., Bipat S., Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2011, 257:674-684.
17. Cancer facts and figs. 2011 2011, American Cancer Society.
18. Pantel K., Alix-Panabieres C., Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 2009, 6:339-351.
19. Robinson P.J. The early detection of liver metastases. Cancer Imaging 2002, 2:1-3.
20. Society A.C. Cancer Facts and Figures 2012.
21. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 1994, 54:3352-3356.
22. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4607-4612.
23. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
24. Fukumura D., Jain R.K. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 2007, 101:937-949.
25. McDonald D.M., Thurston G., Baluk P. Endothelial gaps as sites for plasma leakage in inflammation. Microcirculation 1999, 6:7-22.
26. McDonald D.M., Choyke P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 2003, 9:713-725.
27. Hashizume H., Baluk P., Morikawa S., McLean J.W., Thurston G., Roberge S., Jain R.K., McDonald D.M. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 2000, 156:1363-1380.
28. McDonald D.M., Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002, 62:5381-5385.
29. Karathanasis E., Suryanarayanan S., Balusu S.R., McNeeley K., Sechopoulos I., Karellas A., Annapragada A.V., Bellamkonda R.V. Imaging nanoprobe for prediction of outcome of nanoparticle chemotherapy by using mammography. Radiology 2009, 250:398-406.
30. Toy R., Hayden E., Camann A., Berman Z., Vicente P., Tran E., Meyers J., Pansky J., Peiris P.M., Wu H., Exner A., Wilson D., Ghaghada K.B., Karathanasis E. Multimodal in vivo imaging exposes the voyage of nanoparticles in tumor microcirculation. ACS Nano 2013, 7:3118-3129.
31. Yuan F., Chen Y., Dellian M., Safabakhsh N., Ferrara N., Jain R.K. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14765-14770.
32. Karathanasis E., Chan L., Karumbaiah L., McNeeley K., D'Orsi C.J., Annapragada A.V., Sechopoulos I., Bellamkonda R.V. Tumor vascular permeability to a nanoprobe correlates to tumor-specific expression levels of angiogenic markers. PLoS ONE 2009, 4:e5843.
33. Lee H.J., Cho H.Y., Oh J.H., Namkoong K., Lee J.G., Park J.M., Lee S.S., Huh N., Choi J.W. Simultaneous capture and in situ analysis of circulating tumor cells using multiple hybrid nanoparticles. Biosensors & bioelectronics 2013, 47:508-514.
34. Huang Y.Y., Hoshino K., Chen P., Wu C.H., Lane N., Huebschman M., Liu H., Sokolov K., Uhr J.W., Frenkel E.P., Zhang J.X. Immunomagnetic nanoscreening of circulating tumor cells with a motion controlled microfluidic system. Biomed Microdevices 2013, 15:673-681.
35. Chauhan V.P., Jain R.K. Strategies for advancing cancer nanomedicine. Nat. Mater. 2013, 12:958-962.
36. Piner R.D., Zhu J., Xu F., Hong S., Mirkin C.A. "Dip-Pen" nanolithography. Science 1999, 283:661-663.
37. Canelas D.A., Herlihy K.P., DeSimone J.M. Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1:391-404.
38. Toy R., Peiris P.M., Ghaghada K.B., Karathanasis E. Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. Nanomedicine (Lond) 2014, 9:121-134.
39. Toy R., Hayden E., Shoup C., Baskaran H., Karathanasis E. The effects of particle size, density and shape on margination of nanoparticles in microcirculation. Nanotechnology 2011, 22:115101.
40. Thompson A.J., Mastria E.M., Eniola-Adefeso O. The margination propensity of ellipsoidal micro/nanoparticles to the endothelium in human blood flow. Biomaterials 2013, 34:5863-5871.
41. Namdee K., Thompson A.J., Charoenphol P., Eniola-Adefeso O. Margination propensity of vascular-targeted spheres from blood flow in a microfluidic model of human microvessels. Langmuir 2013, 29:2530-2535.
42. Owens D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
43. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 2003, 42:463-478.
44. Litzinger D.C., Buiting A.M., van Rooijen N., Huang L. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1994, 1190:99-107.
45. Nagayasu A., Uchiyama K., Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 1999, 40:75-87.
46. Ma X., Wu Y., Jin S., Tian Y., Zhang X., Zhao Y., Yu L., Liang X.J. Gold nanoparticles induce autophagosome accumulation through size-dependent nanoparticle uptake and lysosome impairment. ACS Nano 2011, 5:8629-8639.
47. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006, 6:662-668.
48. Kibria G., Hatakeyama H., Ohga N., Hida K., Harashima H. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin alphavbeta3-expressing tumor endothelial cells. Biomaterials 2013, 34:5617-5627.
49. Champion J.A., Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4930-4934.
50. Arnida M.M., Janat-Amsbury A., Ray C.M., Peterson H. Ghandehari, Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm 2011, 77:417-423.
51. Huang X., Li L., Liu T., Hao N., Liu H., Chen D., Tang F. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 2011, 5:5390-5399.
52. Shapiro E.G.a.M. Particles in a shear flow near a solid wall: effect of nonsphericity on forces and velocities. Int. J. Multiphase Flow 1997, 23:155-182.
53. Adriani G., de Tullio M.D., Ferrari M., Hussain F., Pascazio G., Liu X., Decuzzi P. The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials 2012, 33:5504-5513.
54. Doshi N., Prabhakarpandian B., Rea-Ramsey A., Pant K., Sundaram S., Mitragotri S. Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. J Control Release 2010, 146:196-200.
55. Lee S.Y., Ferrari M., Decuzzi P. Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology 2009, 20:495101. (11 pp.).
56. Peiris P.M., Toy R., Doolittle E., Pansky J., Abramowski A., Tam M., Vicente P., Tran E., Hayden E., Camann A., Mayer A., Erokwu B.O., Berman Z., Wilson D., Baskaran H., Flask C.A., Keri R.A., Karathanasis E. Imaging metastasis using an integrin-targeting chain-shaped nanoparticle. ACS Nano 2012, 6:8783-8795.
57. Shuvaev V.V., Ilies M.A., Simone E., Zaitsev S., Kim Y., Cai S., Mahmud A., Dziubla T., Muro S., Discher D.E., Muzykantov V.R. Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano 2011, 5:6991-6999.
58. Kolhar P., Anselmo A.C., Gupta V., Pant K., Prabhakarpandian B., Ruoslahti E., Mitragotri S. Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. Proc Natl Acad Sci U S A 2013.
59. Valencia P.M., Pridgen E.M., Rhee M., Langer R., Farokhzad O.C., Karnik R. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano 2013, 7:10671-10680.
60. Stefanick J.F., Ashley J.D., Kiziltepe T., Bilgicer B. A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. ACS Nano 2013, 7:2935-2947.
61. Ghaghada K.B., Saul J., Natarajan J.V., Bellamkonda R.V., Annapragada A.V. Folate targeting of drug carriers: a mathematical model. J. Control. Release 2005, 104:113-128.
62. Smith B.R., Kempen P., Bouley D., Xu A., Liu Z., Melosh N., Dai H., Sinclair R., Gambhir S.S. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett. 2012, 12:3369-3377.
63. Smith B.R., Cheng Z., De A., Rosenberg J., Gambhir S.S. Dynamic visualization of RGD-quantum dot binding to tumor neovasculature and extravasation in multiple living mouse models using intravital microscopy. Small 2010, 6:2222-2229.
64. Smith B.R., Cheng Z., De A., Koh A.L., Sinclair R., Gambhir S.S. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett. 2008, 8:2599-2606.
65. McNeeley K.M., Annapragada A., Bellamkonda R.V. Decreased circulation time offsets increased efficacy of PEGylated nanocarriers targeting folate receptors of glioma. Nanotechnology 2007, 18:385101.
66. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 2003, 9:6551-6559.
67. Gabizon A., Shmeeda H., Horowitz A.T., Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 2004, 56:1177-1192.
68. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003, 63:7400-7409.
69. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzym. Regul. 2001, 41:189-207.
70. Mayer L.D., Tai L.C., Ko D.S., Masin D., Ginsberg R.S., Cullis P.R., Bally M.B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989, 49:5922-5930.
71. Perrault S.D., Walkey C., Jennings T., Fischer H.C., Chan W.C. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009, 9:1909-1915.
72. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995, 55:3752-3756.
73. Decuzzi P., Causa F., Ferrari M., Netti P.A. The effective dispersion of nanovectors within the tumor microvasculature. Ann. Biomed. Eng. 2006, 34:633-641.
74. Decuzzi P., Ferrari M. Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials 2008, 29:377-384.
75. Gentile F., Ferrari M., Decuzzi P. The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann. Biomed. Eng. 2008, 36:254-261.
76. Netti P.A., Roberge S., Boucher Y., Baxter L.T., Jain R.K. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc. Res. 1996, 52:27-46.
77. Nagamitsu A., Greish K., Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 2009, 39:756-766.
78. Kong G., Braun R.D., Dewhirst M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 2000, 60:4440-4445.
79. Less J.R., Skalak T.C., Sevick E.M., Jain R.K. Microvascular network architecture in a mammary carcinoma. EXS 1992, 61:74-80.
80. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 1988, 48:2641-2658.
81. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 4:806-813.
82. Albanese A., Lam A.K., Sykes E.A., Rocheleau J.V., Chan W.C. Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat Commun 2013, 4:2718.
83. Gavze E., Shapiro M. Motion of inertial spheroidal particles in a shear flow near a solid wall with special application to aerosol transport in microgravity. J. Fluid Mech. 1998, 371:59-79.
84. Hogg A.J. The inertial migration of non-neutrally buoyant spherical particles in two-dimensional shear flows. J. Fluid Mech. 1994, 272:285-318.
85. Gentile F., Chiappini C., Fine D., Bhavane R.C., Peluccio M.S., Cheng M.M., Liu X., Ferrari M., Decuzzi P. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. J. Biomech. 2008, 41:2312-2318.
86. Gentile F., Curcio A., Indolfi C., Ferrari M., Decuzzi P. The margination propensity of spherical particles for vascular targeting in the microcirculation. J. Nanobiotechnology 2008, 6:9.
87. Ghaghada K.B., Saul J., Natarajan J.V., Bellamkonda R.V., Annapragada A.V. Folate targeting of drug carriers: a mathematical model. J. Control. Release 2005, 104:113-128.
88. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9:285-293.
89. Wirtz D., Konstantopoulos K., Searson P.C. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat. Rev. Cancer 2011, 11:512-522.
90. Kim Y.H., Jeon J., Hong S.H., Rhim W.K., Lee Y.S., Youn H., Chung J.K., Lee M.C., Lee D.S., Kang K.W., Nam J.M. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small 2011, 7:2052-2060.
91. van Kasteren S.I., Campbell S.J., Serres S., Anthony D.C., Sibson N.R., Davis B.G. Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18-23.
92. Peiris P.M., Toy R., Abramowski A., Vicente P., Tucci S., Bauer L., Mayer A., Tam M., Doolittle E., Pansky J., Tran E., Lin D., Schiemann W.P., Ghaghada K.B., Griswold M.A., Karathanasis E. Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle. J. Control. Release 2014, 173:51-58.
93. Hainfeld J.F., O'Connor M.J., Dilmanian F.A., Slatkin D.N., Adams D.J., Smilowitz H.M. Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions. Br. J. Radiol. 2011, 84:526-533.
94. Eck W., Nicholson A.I., Zentgraf H., Semmler W., Bartling S. Anti-CD4-targeted gold nanoparticles induce specific contrast enhancement of peripheral lymph nodes in X-ray computed tomography of live mice. Nano Lett. 2010, 10:2318-2322.
95. Reuveni T., Motiei M., Romman Z., Popovtzer A., Popovtzer R. Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study. Int. J. Nanomedicine 2011, 6:2859-2864.
96. Chanda N., Kattumuri V., Shukla R., Zambre A., Katti K., Upendran A., Kulkarni R.R., Kan P., Fent G.M., Casteel S.W., Smith C.J., Boote E., Robertson J.D., Cutler C., Lever J.R., Katti K.V., Kannan R. Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8760-8765.
97. Kim D., Jeong Y.Y., Jon S. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 2010, 4:3689-3696.
98. Popovtzer R., Agrawal A., Kotov N.A., Popovtzer A., Balter J., Carey T.E., Kopelman R. Targeted Gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 2008, 8:4593-4596.
99. Wang H., Zheng L., Peng C., Guo R., Shen M., Shi X., Zhang G. Computed tomography imaging of cancer cells using acetylated dendrimer-entrapped gold nanoparticles. Biomaterials 2011, 32:2979-2988.
100. Kinsella J.M., Jimenez R.E., Karmali P.P., Rush A.M., Kotamraju V.R., Gianneschi N.C., Ruoslahti E., Stupack D., Sailor M.J. X-ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew. Chem. Int. Ed. Engl. 2011, 50:12308-12311.
101. Pan D., Roessl E., Schlomka J.P., Caruthers S.D., Senpan A., Scott M.J., Allen J.S., Zhang H., Hu G., Gaffney P.J., Choi E.T., Rasche V., Wickline S.A., Proksa R., Lanza G.M. Computed tomography in color: NanoK-enhanced spectral CT molecular imaging. Angew. Chem. Int. Ed. Engl. 2010, 49:9635-9639.
102. Anderson C.R., Hu X., Zhang H., Tlaxca J., Decleves A.-E., Houghtaling R., Sharma K., Lawrence M., Ferrara K.W., Rychak J.J. Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Investig. Radiol. 2011, 56:215-224.
103. Dayton P.A., Pearson D., Clark J., Simon S., Schumann P.A., Zutshi R., Matsunaga T.O., Ferrara K.W. Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol. Imaging 2004, 3:125-134.
104. Ellegala D.B., Leong-Poi H., Carpenter J.E., Klibanov A.L., Kaul S., Shaffrey M.E., Sklenar J., Lindner J.R. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003, 108:336-341.
105. Kiessling F., Huppert J., Zhang C., Jayapaul J., Zwick S., Woenne E.C., Mueller M.M., Zentgraf H., Eisenhut M., Addadi Y., Neeman M., Semmler W. Adhesion and endocytotic activity of alpha-v-beta-3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology 2009, 253:462-469.
106. Leong-Poi H. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alphav-integrins. Circulation 2002, 107:455-460.
107. Willmann J.K., Kimura R.H., Deshpande N., Lutz A.M., Cochran J.R., Gambhir S.S. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J. Nucl. Med. 2010, 51:433-440.
108. Pysz M.A., Foygel K., Rosenberg J., Gambhir S.S., Schneider M., Willmann J.K. Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). Radiology 2010, 256:519-527.
109. Willmann J.K., Lutz A.M., Paulmurugan R., Patel M.R., Chu P., Rosenberg J., Gambhir S.S. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008, 248:936-944.
110. Zhang C., Jugold M., Woenne E.C., Lammers T., Morgenstern B., Mueller M.M., Zentgraf H., Bock M., Eisenhut M., Semmler W., Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007, 67:1555-1562.
111. Lee G.Y., Qian W.P., Wang L., Wang Y.A., Staley C.A., Satpathy M., Nie S., Mao H., Yang L. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano 2013, 7:2078-2089.
112. Park J., Kim S., Saw P.E., Lee I.H., Yu M.K., Kim M., Lee K., Kim Y.C., Jeong Y.Y., Jon S. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging. J. Control. Release 2012, 163:111-118.
113. He Y., Song W., Lei J., Li Z., Cao J., Huang S., Meng J., Xu H., Jin Z., Xue H. Anti-CXCR4 monoclonal antibody conjugated to ultrasmall superparamagnetic iron oxide nanoparticles in an application of MR molecular imaging of pancreatic cancer cell lines. Acta Radiol. 2012, 53:1049-1058.
114. Hsieh W.J., Liang C.J., Chieh J.J., Wang S.H., Lai I.R., Chen J.H., Chang F.H., Tseng W.K., Yang S.Y., Wu C.C., Chen Y.L. In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles. Int. J. Nanomedicine 2012, 7:2833-2842.
115. Kresse M., Wagner S., Pfefferer D., Lawaczeck R., Elste V., Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn. Reson. Med. 1998, 40:236-242.
116. John R., Nguyen F.T., Kolbeck K.J., Chaney E.J., Marjanovic M., Suslick K.S., Boppart S.A. Targeted multifunctional multimodal protein-shell microspheres as cancer imaging contrast agents. Mol. Imaging Biol. 2012, 14:17-24.
117. Mulder W.J., Strijkers G.J., Habets J.W., Bleeker E.J., van der Schaft D.W., Storm G., Koning G.A., Griffioen A.W., Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005, 19:2008-2010.
118. Mulder W.J., van der Schaft D.W., Hautvast P.A., Strijkers G.J., Koning G.A., Storm G., Mayo K.H., Griffioen A.W., Nicolay K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 2007, 21:378-383.
119. Kluza E., Jacobs I., Hectors S.J., Mayo K.H., Griffioen A.W., Strijkers G.J., Nicolay K. Dual-targeting of alphavbeta3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Control. Release 2012, 158:207-214.
120. Kluza E., van der Schaft D.W., Hautvast P.A., Mulder W.J., Mayo K.H., Griffioen A.W., Strijkers G.J., Nicolay K. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2010, 10:52-58.
121. Paulis L.E.M., Jacobs I., van den Akker N.M., Geelen T., Molin D.G., Starmans L.W.E., Nicolay K., Strijkers G.J. Targeting of ICAM-1 on vascular endothelium under static and shear stress conditions using a liposomal Gd-based MRI contrast agent. J. Nanobiotechnology 2012, 10.
122. Zhang D., Feng X.Y., Henning T.D., Wen L., Lu W.Y., Pan H., Wu X., Zou L.G. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur. J. Radiol. 2009, 70:180-189.
123. Kamaly N., Kalber T., Thanou M., Bell J.D., Miller A.D. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug. Chem. 2009, 20:648-655.
124. Kaneda M.M., Caruthers S., Lanza G.M., Wickline S.A. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann. Biomed. Eng. 2009, 37:1922-1933.
125. Schmieder A.H., Caruthers S.D., Zhang H., Williams T.A., Robertson J.D., Wickline S.A., Lanza G.M. Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 2008, 22:4179-4189.
126. Boles K.S., Schmieder A.H., Koch A.W., Carano R.A., Wu Y., Caruthers S.D., Tong R.K., Stawicki S., Hu G., Scott M.J., Zhang H., Reynolds B.A., Wickline S.A., Lanza G.M. MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J. 2010, 24:4262-4270.
127. Flament J., Geffroy F., Medina C., Robic C., Mayer J.F., Meriaux S., Valette J., Robert P., Port M., Le Bihan D., Lethimonnier F., Boumezbeur F. In vivo CEST MR imaging of U87 mice brain tumor angiogenesis using targeted LipoCEST contrast agent at 7T. Magn. Reson. Med. 2013, 69:179-187.
128. Konda S.D., Aref M., Wang S., Brechbiel M., Wiener E.C. Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts. MAGMA 2001, 12:104-113.
129. Swanson S.D., Kukowska-Latalla J.F., Patri A.K., Chen C., Ge S., Cao Z., Kotlyar A., East A.T., Baker J.R. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int. J. Nanomedicine 2008, 3:201-210.
130. Tian M., Lu W., Zhang R., Xiong C., Ensor J., Nazario J., Jackson J., Shaw C., Dixon K.A., Miller J., Wright K., Li C., Gupta S. Tumor uptake of hollow gold nanospheres after intravenous and intra-arterial injection: PET/CT study in a rabbit VX2 liver cancer model. Mol. Imaging Biol. 2013, 15:614-624.
131. Kim Y.H., Jeon J., Hong S.H., Rhim W.K., Lee Y.S., Youn H., Chung J.K., Lee M.C., Lee D.S., Kang K.W., Nam J.M. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small 2011, 7:2052-2060.
132. Chen F., Hong H., Zhang Y., Valdovinos H.F., Shi S., Kwon G.S., Theuer C.P., Barnhart T.E., Cai W. In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. ACS Nano 2013, 7:9027-9039.
133. Hu G., Lijowski M., Zhang H., Partlow K.C., Caruthers S.D., Kiefer G., Gulyas G., Athey P., Scott M.J., Wickline S.A., Lanza G.M. Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int. J. Cancer 2007, 120:1951-1957.
134. Aaron J., Nitin N., Travis K., Kumar S., Collier T., Park S.Y., Jose-Yacaman M., Coghlan L., Follen M., Richards-Kortum R., Sokolov K. Plasmon resonance coupling of metal nanoparticles for molecular imaging of carcinogenesis in vivo. J. Biomed. Opt. 2007, 12:034007.
135. El-Sayed I.H., Huang X., El-Sayed M.A. Surface plasmon resonance scattering and absorption of anti-EGFR antibody conjugated gold nanoparticles in cancer diagnostics: applications in oral cancer. Nano Lett. 2005, 5:829-834.
136. Skala M.C., Crow M.J., Wax A., Izatt J.A. Photothermal optical coherence tomography of epiderma growth factor receptor in live cells using immunotargeted gold nanospheres. Nano Lett. 2008, 8:3461-3467.
137. Loo C., Hirsch L., Lee M.-H., Chang E., West J., Halas N., Drezek R. Gold nanoshell bioconjugates for molecular imaging in living cells. Opt. Lett. 2005, 30:1012-1014.
138. Loo C., Lowery A., Halas N., West J., Drezek R. Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 2005, 5:709-711.
139. Durr N.J., Larson T., Smith D.K., Korgel B.A., Sokolov K., Ben-Yakar A. Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods. Nano Lett. 2007, 7:941-945.
140. Huang X., El-Sayed I.H., Qian W., El-Sayed M.A. Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 2006, 128:2115-2120.
141. Jokerst J.V., Miao Z., Zavaleta C., Cheng Z., Gambhir S.S. Affibody-functionalized gold-silica nanoparticles for Raman molecular imaging of the epidermal growth factor receptor. Small 2011, 7:625-633.
142. Setua S., Menon D., Asok A., Nair S., Koyakutty M. Folate receptor targeted, rare-earth oxide nanocrystals for bi-modal fluorescence and magnetic imaging of cancer cells. Biomaterials 2010, 31:714-729.
143. Kim G., Huang S.W., Day K.C., O'Donnell M., Agayan R.R., Day M.A., Kopelman R., Ashkenazi S. Indocyanine-green-embedded PEBBLEs as a contrast agent for photoacoustic imaging. J. Biomed. Opt. 2007, 12:044020.
144. Olson E.S., Jiang T., Aguilera T.A., Nguyen Q.T., Ellies L.G., Scadeng M., Tsien R.Y. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4311-4316.
145. Xi L., Satpathy M., Zhao Q., Qian W., Yang L., Jiang H. HER-2/neu targeted delivery of a nanoprobe enables dual photoacoustic and fluorescence tomography of ovarian cancer. Nanomedicine 2013, 10:669-677.
146. Gao J., Chen K., Luong R., Bouley D.M., Mao H., Qiao T., Gambhir S.S., Cheng Z. A novel clinically translatable fluorescent nanoparticle for targeted molecular imaging of tumors in living subjects. Nano Lett. 2012, 12:281-286.
147. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22:969-976.
148. Chen J., Cheng D., Li J., Wang Y., Guo J.X., Chen Z.P., Cai B.C., Yang T. Influence of lipid composition on the phase transition temperature of liposomes composed of both DPPC and HSPC. Drug Dev. Ind. Pharm. 2013, 39:197-204.
149. Lijowski M., Caruthers S., Hu G., Zhang H., Scott M.J., Williams T., Erpelding T., Schmieder A.H., Kiefer G., Gulyas G., Athey P.S., Gaffney P.J., Wickline S.A., Lanza G.M. High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Investig. Radiol. 2009, 44:15-22.
150. Thakor A.S., Gambhir S.S. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J. Clin. 2013, 63:395-418.
151. Penet M.F., Artemov D., Farahani K., Bhujwalla Z.M. MR - eyes for cancer: looking within an impenetrable disease. NMR Biomed. 2013, 26:745-755.
152. Ma D., Gulani V., Seiberlich N., Liu K., Sunshine J.L., Duerk J.L., Griswold M.A. Magnetic resonance fingerprinting. Nature 2013, 495:187-192.
153. Runge V.M. Current technological advances in magnetic resonance with critical impact for clinical diagnosis and therapy. Investig. Radiol. 2013, 48:869-877.
154. Ghaghada K.B., Bockhorst K.H., Mukundan S., Annapragada A.V., Narayana P.A. High-resolution vascular imaging of the rat spine using liposomal blood pool MR agent. AJNR Am. J. Neuroradiol. 2007, 28:48-53.
155. Mieszawska A.J., Mulder W.J., Fayad Z.A., Cormode D.P. Multifunctional gold nanoparticles for diagnosis and therapy of disease. Mol. Pharm. 2013, 10:831-847.
156. Cormode D.P., Naha P.C., Fayad Z.A. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol. Imaging 2014, 9:37-52.
157. Gu Z., Yan L., Tian G., Li S., Chai Z., Zhao Y. Recent advances in design and fabrication of upconversion nanoparticles and their safe theranostic applications. Adv. Mater. 2013, 25:3758-3779.
158. Zeng S., Tsang M.K., Chan C.F., Wong K.L., Hao J. PEG modified BaGdF(5):Yb/Er nanoprobes for multi-modal upconversion fluorescent, in vivo X-ray computed tomography and biomagnetic imaging. Biomaterials 2012, 33:9232-9238.
159. Ma J., Huang P., He M., Pan L., Zhou Z., Feng L., Gao G., Cui D. Folic acid-conjugated LaF3:Yb, Tm@SiO2 nanoprobes for targeting dual-modality imaging of upconversion luminescence and X-ray computed tomography. J. Phys. Chem. B 2012, 116:14062-14070.
160. Wang C., Cheng L., Liu Z. Upconversion nanoparticles for photodynamic therapy and other cancer therapeutics. Theranostics 2013, 3:317-330.
161. Chien Y.H., Chou Y.L., Wang S.W., Hung S.T., Liau M.C., Chao Y.J., Su C.H., Yeh C.S. Near-infrared light photocontrolled targeting, bioimaging, and chemotherapy with caged upconversion nanoparticles in vitro and in vivo. ACS Nano 2013, 7:8516-8528.
162. Cui S., Yin D., Chen Y., Di Y., Chen H., Ma Y., Achilefu S., Gu Y. In vivo targeted deep-tissue photodynamic therapy based on near-infrared light triggered upconversion nanoconstruct. ACS Nano 2013, 7:676-688.
163. Pan D., Schirra C.O., Senpan A., Schmieder A.H., Stacy A.J., Roessl E., Thran A., Wickline S.A., Proska R., Lanza G.M. An early investigation of ytterbium nanocolloids for selective and quantitative "multicolor" spectral CT imaing. ACS Nano 2012, 6:3364-3370.
164. Oh M.H., Lee N., Kim H., Park S.P., Piao Y., Lee J., Jun S.W., Moon W.K., Choi S.H., Hyeon T. Large-scale synthesis of bioinert tantalum oxide nanoparticles for X-ray computed tomography imaging and bimodal image-guided sentinel lymph node mapping. J. Am. Chem. Soc. 2011, 133:5508-5515.
165. Liu R., Tian B., Gearing M., Hunter S., Ye K., Mao Z. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7570-7575.
166. Zhou J., Patel T.R., Sirianni R.W., Strohbehn G., Zheng M.Q., Duong N., Schafbauer T., Huttner A.J., Huang Y., Carson R.E., Zhang Y., Sullivan D.J., Piepmeier J.M., Saltzman W.M. Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:11751-11756.
167. Anderson C.R., Rychak J.J., Backer M., Backer J., Ley K., Klibanov A.L. scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis. Investig. Radiol. 2010, 45:579-585.
168. Saul J.M., Annapragada A.V., Bellamkonda R.V. A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control. Release 2006, 114:277-287.
169. Bulte J.W., Kraitchman D.L. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004, 17:484-499.
170. Jun Y.-W., Seo J.-W., Cheon J. Nanoscaling laws of magnetic nanoparticles and their applicabilities in biomedical sciences. Acc. Chem. Res. 2008, 41:179-189.
171. Smolensky E.D., Park H.Y., Zhou Y., Rolla G.A., Marjanska M., Botta M., Pierre V.C. Scaling laws at the nano size: the effect of particle size and shape on the magnetism and relaxivity of iron oxide nanoparticle contrast agents. J. Mater. Chem. B 2013, 1:2818-2828.
172. Artemov D., Mori N., Okollie B., Bhujwalla Z.M. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 2003, 49:403-408.
173. Langereis S., Geelen T., Grull H., Strijkers G.J., Nicolay K. Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery. NMR Biomed. 2013, 26:728-744.
174. Kelly K.A., Allport J.R., Tsourkas A., Shinde-Patil V.R., Josephson L., Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 2005, 96:327-336.
175. Ghaghada K.B., Ravoori M., Sabapathy D., Bankson J., Kundra V., Annapragada A. New dual mode gadolinium nanoparticle contrast agent for magnetic resonance imaging. PLoS ONE 2009, 4:e7628.
176. Kok M.B., Strijkers G.J., Nicolay K. Dynamic changes in 1H-MR relaxometric properties of cell-internalized paramagnetic liposomes, as studied over a five-day period. Contrast Media Mol. Imaging 2011, 6:69-76.
177. Laurent S., Vander Elst L., Thirifays C., Muller R.N. Paramagnetic liposomes: inner versus outer membrane relaxivity of DPPC liposomes incorporating lipophilic gadolinium complexes. Langmuir 2008, 24:4347-4351.
178. Laurent S., Vander Elst L., Thirifays C., Muller R.N. Relaxivities of paramagnetic liposomes: on the importance of the chain type and the length of the amphiphilic complex. Eur. Biophys. J. 2008, 37:1007-1014.
179. Santra S., Jativa S.D., Kaittanis C., Normand G., Grimm J., Perez J.M. Gadolinium-encapsulating iron oxide nanoprobe as activatable NMR/MRI contrast agent. ACS Nano 2012, 6:7281-7294.
180. Opina A.C., Ghaghada K.B., Zhao P., Kiefer G., Annapragada A., Sherry A.D. TmDOTA-tetraglycinate encapsulated liposomes as pH-sensitive LipoCEST agents. PLoS ONE 2011, 6:e27370.
181. Castelli D.D., Terreno E., Longo D., Aime S. Nanoparticle-based chemical exchange saturation transfer (CEST) agents. NMR Biomed. 2013, 26:839-849.
182. Vinogradov E., Sherry A.D., Lenkinski R.E. CEST: from basic principles to applications, challenges and opportunities. J. Magn. Reson. 2013, 229:155-172.
183. Elias D.R., Poloukhtine A., Popik V., Tsourkas A. Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine: NBM 2013, 9:194-201.
184. Gay L.J., Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 2011, 11:123-134.
185. Felding-Habermann B., Habermann R., Saldivar E., Ruggeri Z.M. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow. J. Biol. Chem. 1996, 271:5892-5900.
186. McCarty O.J., Mousa S.A., Bray P.F., Konstantopoulos K. Immobilized platelets support human colon carcinoma cell tethering, rolling, and firm adhesion under dynamic flow conditions. Blood 2000, 96:1789-1797.
187. Arnaout M.A., Mahalingam B., Xiong J.P. Integrin structure, allostery, and bidirectional signaling. Annu. Rev. Cell Dev. Biol. 2005, 21:381-410.
188. Felding-Habermann B., O'Toole T.E., Smith J.W., Fransvea E., Ruggeri Z.M., Ginsberg M.H., Hughes P.E., Pampori N., Shattil S.J., Saven A., Mueller B.M. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1853-1858.
189. Lorger M., Krueger J.S., O'Neal M., Staflin K., Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:10666-10671.
190. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
191. Lee J.H., Huh Y.M., Jun Y.W., Seo J.W., Jang J.T., Song H.T., Kim S., Cho E.J., Yoon H.G., Suh J.S., Cheon J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 2007, 13:95-99.
192. Pan D., Schmieder A.H., Wickline S.A., Lanza G.M. Manganese-based MRI contrast agents: past, present and future. Tetrahedron 2011, 67:8431-8444.
193. Baek M.J., Park J.Y., Xu W., Kattel K., Kim H.G., Lee E.J., Patel A.K., Lee J.J., Chang Y., Kim T.J., Bae J.E., Chae K.S., Lee G.H. Water-soluble MnO nanocolloid for a molecular T1 MR imaging: a facile one-pot synthesis, in vivo T1 MR images, and account for relaxivities. ACS Appl. Mater. Interfaces 2010, 2:2949-2955.
194. Xia A., Chen M., Gao Y., Wu D., Feng W., Li F. Gd3+ complex-modified NaLuF4-based upconversion nanophosphors for trimodality imaging of NIR-to-NIR upconversion luminescence, X-Ray computed tomography and magnetic resonance. Biomaterials 2012, 33:5394-5405.
195. Lee J., Lee T.S., Ryu J., Hong S., Kang M., Im K., Kang J.H., Lim S.M., Park S., Song R. RGD peptide-conjugated multimodal NaGdF4:Yb3+/Er3+ nanophosphors for upconversion luminescence, MR, and PET imaging of tumor angiogenesis. J. Nucl. Med. 2013, 54:96-103.
196. Shen J.W., Yang C.X., Dong L.X., Sun H.R., Gao K., Yan X.P. Incorporation of computed tomography and magnetic resonance imaging function into NaYF4:Yb/Tm upconversion nanoparticles for in vivo trimodal bioimaging. Anal. Chem. 2013, 85:12166-12172.
197. Chen J., Lanza G.M., Wickline S.A. Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2:431-440.
198. Southworth R., Kaneda M., Chen J., Zhang L., Zhang H., Yang X., Razavi R., Lanza G., Wickline S.A. Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons. Nanomedicine: NBM 2009, 5:359-367.
199. Giraudeau C., Geffroy F., Meriaux S., Boumezbeur F., Robert P., Port M., Robic C., Le Bihan D., Lethimonnier F., Valette J. 19F molecular MR imaging for detection of brain tumor angiogenesis: in vivo validation using targeted PFOB nanoparticles. Angiogenesis 2013, 16:171-179.
200. Srinivas M., Boehm-Sturm P., Figdor C.G., de Vries I.J., Hoehn M. Labeling cells for in vivo tracking using (19)F MRI. Biomaterials 2012, 33:8830-8840.
201. Ahrens E.T., Bulte J.W. Tracking immune cells in vivo using magnetic resonance imaging, Nature reviews. Immunology 2013, 13:755-763.
202. Atkins T.M., Cassidy M.C., Lee M., Ganguly S., Marcus C.M., Kauzlarich S.M. Synthesis of long T(1) silicon nanoparticles for hyperpolarized (2)(9)Si magnetic resonance imaging. ACS Nano 2013, 7:1609-1617.
203. Cassidy M.C., Chan H.R., Ross B.D., Bhattacharya P.K., Marcus C.M. In vivo magnetic resonance imaging of hyperpolarized silicon particles. Nat. Nanotechnol. 2013, 8:363-368.
204. Bao A., Goins B., Klipper R., Negrete G., Phillips W.T. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J. Pharmacol. Exp. Ther. 2004, 308:419-425.
205. Elbayoumi T.A., Torchilin V.P. Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:1196-1205.
206. Nahrendorf M., Zhang H., Hembrador S., Panizzi P., Sosnovik D.E., Aikawa E., Libby P., Swirski F.K., Weissleder R. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008, 117:379-387.
207. Nahrendorf M., Keliher E., Marinelli B., Waterman P., Feruglio P.F., Fexon L., Pivovarov M., Swirski F.K., Pittet M.J., Vinegoni C., Weissleder R. Hybrid PET-optical imaging using targeted probes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7910-7915.
208. Yang X., Hong H., Grailer J.J., Rowland I.J., Javadi A., Hurley S.A., Xiao Y., Yang Y., Zhang Y., Nickles R.J., Cai W., Steeber D.A., Gong S. cRGD-functionalized, DOX-conjugated, and (6)(4)Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011, 32:4151-4160.
209. Cai W., Chen K., Li Z.B., Gambhir S.S., Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med. 2007, 48:1862-1870.
210. Chen K., Li Z.B., Wang H., Cai W., Chen X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2235-2244.
211. Liu T.W., MacDonald T.D., Jin C.S., Gold J.M., Bristow R.G., Wilson B.C., Zheng G. Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS Nano 2013, 7.
212. Chen F., Hong H., Shi S., Goel S., Valdovinos H.F., Hernandez R., Theuer C.P., Barnhart T.E., Cai W. Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci. Rep. 2014, 4:5080.
213. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2007, 2:47-52.
214. Ruggiero A., Villa C.H., Holland J.P., Sprinkle S.R., May C., Lewis J.S., Scheinberg D.A., McDevitt M.R. Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. Int. J. Nanomedicine 2010, 5:783-802.
215. Key J., Leary J.F. Nanoparticles for multimodal in vivo imaging in nanomedicine. Int. J. Nanomedicine 2014, 9:711-726.
216. Luo S., Zhang E., Su Y., Cheng T., Shi C. A review of NIR dyes in cancer targeting and imaging. Biomaterials 2011, 32:7127-7138.
217. Leimgruber A., Berger C., Cortez-Retamozo V., Etzrodt M., Figueirdo J.L., Kohler R.H., Elpek N., Mempel T.R., Swirski F.K., Nahrendorf M., Weissleder R., Pittet M.J. Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle. Neoplasia 2009, 11:459-468.
218. Yang K., Zhao C., Cao Y.A., Tang H., Bai Y.L., Huang H., Zhao C.R., Chen R., Zhao D. In vivo and in situ imaging of head and neck squamous cell carcinoma using near-infrared fluorescent quantum dot probes conjugated with epidermal growth factor receptor monoclonal antibodies in mice. Oncol. Rep. 2012, 27:1925-1931.
219. Hellebust A., Richards-Kortum R. Advances in molecular imaging: targeted optical contrast agents for cancer diagnostics. Nanomedicine (Lond) 2012, 7:429-445.
220. Skrabalak S.E., Chen J., Au L., Lu X., Li X., Xia Y. Gold nanocages for biomedical applications. Adv. Mater. 2007, 19:3177-3184.
221. Skrabalak S.E., Chen J., Sun Y., Lu X., Au L., Cobley C.M., Xia Y. Gold nanocages: synthesis, properties, and applications. Acc. Chem. Res. 2008, 41:1587-1595.
222. Kircher M.F., de la Zerda A., Jokerst J.V., Zavaleta C.L., Kempen P.J., Mittra E., Pitter K., Huang R., Campos C., Habte F., Sinclair R., Brennan C.W., Mellinghoff I.K., Holland E.C., Gambhir S.S. A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat. Med. 2012, 18:829-834.
223. Petersen A.L., Hansen A.E., Gabizon A., Andresen T.L. Liposome imaging agents in personalized medicine. Adv. Drug Deliv. Rev. 2012, 64:1417-1435.
224. Moding E.J., Clark D.P., Qi Y., Li Y., Ma Y., Ghaghada K., Johnson G.A., Kirsch D.G., Badea C.T. Dual-energy micro-computed tomography imaging of radiation-induced vascular changes in primary mouse sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 2013, 85:1353-1359.
225. Clark D.P., Ghaghada K., Moding E.J., Kirsch D.G., Badea C.T. In vivo characterization of tumor vasculature using iodine and gold nanoparticles and dual energy micro-CT. Phys. Med. Biol. 2013, 58:1683-1704.
226. Deng L., Ke X., He Z., Yang D., Gong H., Zhang Y., Jing X., Yao J., Chen J. A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer. Int. J. Nanomedicine 2012, 7:5053-5065.
227. Das M., Mishra D., Dhak P., Gupta S., Maiti T.K., Basak A., Pramanik P. Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging. Small 2009, 5:2883-2893.
228. Lo S.T., Kumar A., Hsieh J.T., Sun X. Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry. Mol. Pharm. 2013, 10:793-812.
229. Santra S., Kaittanis C., Grimm J., Perez J.M. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small 2009, 5:1862-1868.
230. Gautier J., Allard-Vannier E., Munnier E., Souce M., Chourpa I. Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. J. Control. Release 2013, 169:48-61.
231. Lee G.Y., Qian W.P., Wang L., Wang Y.A., Staley C.A., Satpathy M., Nie S., Mao H., Yang L. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer. ACS Nano 2013, 7:2078-2089.
232. Agemy L., Sugahara K.N., Kotamraju V.R., Gujraty K., Girard O.M., Kono Y., Mattrey R.F., Park J.H., Sailor M.J., Jimenez A.I., Cativiela C., Zanuy D., Sayago F.J., Aleman C., Nussinov R., Ruoslahti E. Nanoparticle-induced vascular blockade in human prostate cancer. Blood 2010, 116:2847-2856.
233. Kenny G.D., Kamaly N., Kalber T.L., Brody L.P., Sahuri M., Shamsaei E., Miller A.D., Bell J.D. Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J. Control. Release 2011, 149:111-116.
234. Gianella A., Jarzyna P.A., Mani V., Ramachandran S., Calcagno C., Tang J., Kann B., Dijk W.J., Thijssen V.L., Griffioen A.W., Storm G., Fayad Z.A., Mulder W.J. Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano 2011, 5:4422-4433.
235. Chen Z., Penet M.F., Nimmagadda S., Li C., Banerjee S.R., Winnard P.T., Artemov D., Glunde K., Pomper M.G., Bhujwalla Z.M. PSMA-targeted theranostic nanoplex for prostate cancer therapy. ACS Nano 2012, 6:7752-7762.
236. Kao H.W., Lin Y.Y., Chen C.C., Chi K.H., Tien D.C., Hsia C.C., Lin M.H., Wang H.E. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model. Bioorg. Med. Chem. Lett. 2013, 23:3180-3185.
237. Li Z., Jin Q., Huang C., Dasa S., Chen L., Yap L.P., Liu S., Cai H., Park R., Conti P.S. Trackable and targeted phage as positron emission tomography (PET) agent for cancer imaging. Theranostics 2011, 1:371-380.
238. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910.
239. Chen W., Bardhan R., Bartels M., Perez-Torres C., Pautler R.G., Halas N.J., Joshi A. A molecularly targeted theranostic probe for ovarian cancer. Mol. Cancer Ther. 2010, 9:1028-1038.
240. Yang H.W., Liu H.L., Li M.L., Hsi I.W., Fan C.T., Huang C.Y., Lu Y.J., Hua M.Y., Chou H.Y., Liaw J.W., Ma C.C., Wei K.C. Magnetic gold-nanorod/PNIPAAmMA nanoparticles for dual magnetic resonance and photoacoustic imaging and targeted photothermal therapy. Biomaterials 2013, 34:5651-5660.
241. Yue C., Liu P., Zheng M., Zhao P., Wang Y., Ma Y., Cai L. IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials 2013, 34:6853-6861.
242. Benachour H., Seve A., Bastogne T., Frochot C., Vanderesse R., Jasniewski J., Miladi I., Billotey C., Tillement O., Lux F., Barberi-Heyob M. Multifunctional peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI. Theranostics 2012, 2:889-904.
243. Shi J., Yu X., Wang L., Liu Y., Gao J., Zhang J., Ma R., Liu R., Zhang Z. PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy, targeted drug delivery and MR imaging. Biomaterials 2013, 34:9666-9677.
244. Yang L., Sajja H.K., Cao Z., Qian W., Bender L., Marcus A.I., Lipowska M., Wood W.C., Wang Y.A. uPAR-targeted optical imaging contrasts as theranostic agents for tumor margin detection. Theranostics 2013, 4:106-118.
245. Agdeppa E.D., Spilker M.E. A review of imaging agent development. AAPS J. 2009, 2:286-299.
246. Nunn A.D. The cost of developing imaging agents for routine clinical use. Investig. Radiol. 2006, 41:206-212.
247. Gorovets A., Marzella L., Rieves D., Yang L. Efficacy considerations for U.S. Food and Drug Administration approval of diagnostic radiopharmaceuticals. J. Nucl. Med. 2013, 54:1479-1484.
248. Farrell D., Ptak K., Panaro N.J., Grodzinski P. Nanotechnology-based cancer therapeutics-promise and challenge-lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm. Res. 2011, 28:273-278.
249. Zamboni W.C., Torchilin V., Patri A.K., Hrkach J., Stern S., Lee R., Nel A., Panaro N.J., Grodzinski P. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin. Cancer Res. 2012, 18:3229-3241.
250. Szebeni J., Muggia F., Gabizon A., Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv. Drug Deliv. Rev. 2011, 63:1020-1030.
251. Re F., Moresco R., Masserini M. Nanoparticles for neuroimaging. J. Phys. D: Appl. Phys. 2012, 45:073001.